Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and immune checkpoint inhibitors (ICIs) have been shown to significantly improve the survival of metastatic NSCLC patients with mutant and wild-type EGFR, respectively (4, 5). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.